drugset
drugset / Trial / NCT05657613

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

NCT05657613 ↗

Phase 1 Completed 60 enrolled CTI BioPharma PPD Development, LP · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.

Timeline

Start
2023-01-03
Primary completion
2023-06-08
Completion
2023-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified 125 mg Oral
Subject Caffeine Small molecule 100 mg Oral
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Fluconazole Small molecule 200 mg Oral
Subject Metformin Small molecule 500 mg Oral
Subject Midazolam Small molecule 2 mg Oral
Subject Omeprazole Other / unclassified 20 mg Oral
Subject Pacritinib Small molecule 200 mg Oral
Subject Rosuvastatin Small molecule 5 mg Oral

Indications

No indication recorded.